Drugs that contain Rilpivirine Hydrochloride

1. Edurant patents expiration

EDURANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7067522 JANSSEN PRODS 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
Dec, 2019

(4 years ago)

US6838464 JANSSEN PRODS 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
Feb, 2021

(3 years ago)

US8080551 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 10 days ago)

US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(a year from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(1 year, 8 months ago)

US7638522 JANSSEN PRODS Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
Apr, 2023

(1 year, 7 days ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 26, 2018
M(M-223) Feb 01, 2021
New Chemical Entity Exclusivity(NCE) May 20, 2016

NCE-1 date: 21 May, 2015

Market Authorisation Date: 20 May, 2011

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy


More Information on Dosage

EDURANT family patents

Family Patents